open access
Sensitivity and specificity of nuclear medicines (DTPA and DMSA) with magnetic resonance imaging in diagnosing bone metastasis
, 2, 1, 2
Affiliations- Department of Radiology, King Abdulaziz University Hospital, Jeddah, Saudi Arabia
- Radiology Sciences Department, King Abdulaziz University, Jeddah, Saudi Arabia
open access
Abstract
Background: The frequency of bone metastases in individuals increases at advanced stages of cancer, mostly in patients suffering from lung, breast, or prostate cancer. The study aims to evaluate the effectiveness of bone metastases diagnosis of nuclear medicine, CT scan, and MRI in detecting bone metastases among patients with lung, breast, and prostate carcinoma. Material and methods: Retrospective study design was adopted for the analysis of 120 recruited patients (with the presence of bone metastasis) following a series of examinations and tests. Results: Better sensitivity (73.33%) and specificity (94.66%) for MRI as compared to SPECT. MRI also proved to be more sensitive (68%) and specific (95.74%), as compared to the findings of the CT scan. Conclusions: The results conclude that MRI provided favorable diagnostic performance for bone metastasis. It emphasizes that diagnosis using MRI may enable practitioners to devise optimal carcinoma treatment strategies. The healthcare practitioners need to assess the MRI findings to determine improved treatment plans.
Abstract
Background: The frequency of bone metastases in individuals increases at advanced stages of cancer, mostly in patients suffering from lung, breast, or prostate cancer. The study aims to evaluate the effectiveness of bone metastases diagnosis of nuclear medicine, CT scan, and MRI in detecting bone metastases among patients with lung, breast, and prostate carcinoma. Material and methods: Retrospective study design was adopted for the analysis of 120 recruited patients (with the presence of bone metastasis) following a series of examinations and tests. Results: Better sensitivity (73.33%) and specificity (94.66%) for MRI as compared to SPECT. MRI also proved to be more sensitive (68%) and specific (95.74%), as compared to the findings of the CT scan. Conclusions: The results conclude that MRI provided favorable diagnostic performance for bone metastasis. It emphasizes that diagnosis using MRI may enable practitioners to devise optimal carcinoma treatment strategies. The healthcare practitioners need to assess the MRI findings to determine improved treatment plans.
Keywords
bone; metastasis; magnetic resonance imaging; nuclear medicine
About this articleTitle
Sensitivity and specificity of nuclear medicines (DTPA and DMSA) with magnetic resonance imaging in diagnosing bone metastasis
Journal
Issue
Article type
Research paper
Pages
85-88
Published online
2022-06-27
Page views
4216
Article views/downloads
597
DOI
Pubmed
Bibliographic record
Nucl. Med. Rev 2022;25(2):85-88.
Keywords
bone
metastasis
magnetic resonance imaging
nuclear medicine
Authors
Shoaa G. Shetewi
Jaber Alyami
Bander S. Al Mutairi
Saeed M. Bafaraj
References (24)- Welch DR, Hurst DR. Defining the Hallmarks of Metastasis. Cancer Res. 2019; 79(12): 3011–3027.
- Esposito M, Guise T, Kang Y. The Biology of Bone Metastasis. Cold Spring Harb Perspect Med. 2018; 8(6).
- Halabi S, Kelly WK, Ma H, et al. Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer. J Clin Oncol. 2016; 34(14): 1652–1659.
- Parker C, Gillessen S, Heidenreich A, et al. ESMO Guidelines Committee. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015; 26 Suppl 5: v69–v77.
- Sevimli R, Korkmaz MF. Analysis of orthopedic surgery of patients with metastatic bone tumors and pathological fractures. J Int Med Res. 2018; 46(8): 3262–3267.
- Łukaszewski B, Nazar J, Goch M, et al. Diagnostic methods for detection of bone metastases. Contemp Oncol (Pozn). 2017; 21(2): 98–103.
- Glaudemans A, Lam M, Veltman N, et al. The Contribution Of Nuclear Medicine In The Diagnosis Of Bone Metastases. Bone Metastases. 2009: 137–162.
- Kim JH, Lee B, Chung BI, et al. Diagnostic Performance of Magnetic Resonance Imaging for the Detection of Bone Metastasis in Prostate Cancer: A Systematic Review and Meta-analysis. Eur Urol. 2018; 73(1): 81–91.
- Macedo F, Ladeira K, Pinho F, et al. Bone Metastases: An Overview. Oncol Rev. 2017; 11(1): 321.
- Lecouvet FE, Talbot JN, Messiou C, et al. EORTC Imaging Group. Monitoring the response of bone metastases to treatment with Magnetic Resonance Imaging and nuclear medicine techniques: a review and position statement by the European Organisation for Research and Treatment of Cancer imaging group. Eur J Cancer. 2014; 50(15): 2519–2531.
- Qu X, Huang X, Yan W, et al. A meta-analysis of ¹⁸FDG-PET-CT, ¹⁸FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with lung cancer. Eur J Radiol. 2012; 81(5): 1007–1015.
- Huysse W, Lecouvet F, Castellucci P, et al. Prospective Comparison of F-18 Choline PET/CT Scan Versus Axial MRI for Detecting Bone Metastasis in Biochemically Relapsed Prostate Cancer Patients. Diagnostics (Basel). 2017; 7(4): 56.
- Clézardin P. Pathophysiology of bone metastases from solid malignancies. Joint Bone Spine. 2017; 84(6): 677–684.
- Borofsky S, George AK, Gaur S, et al. What Are We Missing? False-Negative Cancers at Multiparametric MR Imaging of the Prostate. Radiology. 2018; 286(1): 186–195.
- Hamaoka T, Madewell JE, Podoloff DA, et al. Bone imaging in metastatic breast cancer. J Clin Oncol. 2004; 22(14): 2942–2953.
- Hawass NE. Comparing the sensitivities and specificities of two diagnostic procedures performed on the same group of patients. Br J Radiol. 1997; 70(832): 360–366.
- Shen G, Deng H, Hu S, et al. Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol. 2014; 43(11): 1503–1513.
- Bafaraj SM. Significance of nuclear medicine scan in comparison with diethylenetriamine pentaacetic acid and ultrasound imaging in diagnosing renal disorders: An observational study. Medicine (Baltimore). 2020; 99(36): e22038.
- Balci TA, Ciftci I, Karaoglu A. Incidental DTPA and DMSA uptake during renal scanning in unknown bone metastases. Ann Nucl Med. 2006; 20(5): 365–369.
- Shen G, Deng H, Hu S, et al. Comparison of choline-PET/CT, MRI, SPECT, and bone scintigraphy in the diagnosis of bone metastases in patients with prostate cancer: a meta-analysis. Skeletal Radiol. 2014; 43(11): 1503–1513.
- Damle NA, Bal C, Bandopadhyaya GP, et al. The role of 18F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and 99mTc-MDP bone scan. Jpn J Radiol. 2013; 31(4): 262–269.
- Fahmy H, Yassin H, Muhamed I, et al. Evaluation of the Efficiency of 99mTc-DMSA as a Radiopharmaceutical in Dynamic Renal Scans. Erciyes Tıp Dergisi/Erciyes Medical Journal. 2018; 40(3): 140–147.
- Kimura T. Multidisciplinary Approach for Bone Metastasis: A Review. Cancers (Basel). 2018; 10(6).
- Loud JT, Murphy J. Cancer Screening and Early Detection in the 21 Century. Semin Oncol Nurs. 2017; 33(2): 121–128.
